Reven Announces Coronavirus Treatment Acceleration Program (CTAP) Submission to the FDA

FOR IMMEDIATE RELEASE Reven Announces Coronavirus Treatment Acceleration Program (CTAP) Submission to the FDA Golden, Colorado, Friday, April 3, 2020 3:00pm MDT – Reven, LLC, a biopharmaceutical company that is developing its flagship product Rejuveinix (RJX) for patients with vascular and metabolic related health conditions, announced today that it has submitted a proposal to the [...]

Reven Announces Coronavirus Treatment Acceleration Program (CTAP) Submission to the FDA2020-04-03T16:54:41-04:00

2020/03/28 Reven News Press

A Phase 1, Double-blind, Placebo-controlled, Randomized, Two-Part, Ascending Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Rejuveinix (RJX) in Healthy Participants. Click here for the full study details

2020/03/28 Reven News Press2020-03-28T18:09:11-04:00

2020/03/23 Reven News Press

Reven successfully completes Phase I clinical trials and is pleased to announce completion with no Serious Adverse Events and no Unexpected Adverse Events.  Results are expected to be submitted to the FDA during the next few weeks.

2020/03/23 Reven News Press2020-03-25T11:54:52-04:00

2020/03/22 Reven News Press

Reven announces Phase II Clinical Development plans for upcoming human efficacy trials.  These trials include exploring efficacy as an adjunct therapy for patients suffering Critical Limb Ischemia.  Additional areas of focus in separate trials will be for chronic wound healing and post-surgical recovery support in orthopedic procedures.  Enrollment for these trials is expected to begin [...]

2020/03/22 Reven News Press2020-03-25T12:10:12-04:00

2020/03/21 Reven News Press

Reven will soon kick off a social media campaign to get the word out about the exciting developments relative to RJX moving through the regulatory pathway. Please seek us out on Facebook, Instagram, Twitter, LinkedIn and like/comment on our posts as they appear. We will post things as frequently as possible so everyone may stay [...]

2020/03/21 Reven News Press2020-03-25T12:10:19-04:00